Literature DB >> 29954769

A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Afsaneh Shirani1, Gregory F Wu1, Caterina Giannini2, Anne H Cross1.   

Abstract

Tumefactive appearing lesions on brain imaging can cause a diagnostic dilemma. We report a middle-aged man who presented with right-sided optic neuritis. A brain MRI showed enhancement of the right optic nerve, and non-enhancing white matter lesions including a 3 cm right frontal lesion with adjacent gyral expansion. Cerebrospinal fluid analysis showed five oligoclonal bands not present in serum. Glatiramer acetate was started for suspected tumefactive multiple sclerosis (MS). A follow-up brain MRI 6 months later showed persistence of the frontal gyral expansion. A brain biopsy led to the diagnosis of an oligodendroglioma, isocitrate dehydrogenase-mutant and 1 p/19q co-deleted (WHO grade II), managed with surgical resection and radiotherapy. Postoperative brain MRI showed a new enhancing periventricular lesion, making the choice of optimal disease-modifying therapy for MS challenging. This case highlights the possibility of coexistence of MS and oligodendroglioma, and emphasises the importance of a tissue diagnosis when atypical MS imaging features are present. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  multiple sclerosis; neuroimaging; neurooncology

Mesh:

Substances:

Year:  2018        PMID: 29954769      PMCID: PMC6040514          DOI: 10.1136/bcr-2018-225318

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.

Authors:  Sasa Sega; Alenka Horvat; Mara Popovic
Journal:  Clin Neurol Neurosurg       Date:  2005-12-27       Impact factor: 1.876

2.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-1997. A 50-year-old woman with multiple sclerosis and an enlarging frontal-lobe mass.

Authors:  D Paydarfar; S M de la Monte
Journal:  N Engl J Med       Date:  1997-04-17       Impact factor: 91.245

3.  Balo's concentric sclerosis: a variant of multiple sclerosis associated with oligodendroglioma.

Authors:  S K Shankar; T V Rao; V K Srivastav; S Narula; T Asha; S Das
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

Review 4.  Multiple sclerosis and oligodendroglioma.

Authors:  A J Green; A W Bollen; M S Berger; J R Oksenberg; S L Hauser
Journal:  Mult Scler       Date:  2001-08       Impact factor: 6.312

5.  Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?

Authors:  Elaine Kingwell; Helen Tremlett
Journal:  Expert Rev Neurother       Date:  2009-09       Impact factor: 4.618

6.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

Review 7.  Concurrence of multiple sclerosis and brain tumors.

Authors:  Domenico Plantone; Rosaria Renna; Emilia Sbardella; Tatiana Koudriavtseva
Journal:  Front Neurol       Date:  2015-03-04       Impact factor: 4.003

Review 8.  Oligodendroglioma: pathology, molecular mechanisms and markers.

Authors:  Pieter Wesseling; Martin van den Bent; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

9.  Multiple sclerosis and oligodendroglioma: an exceptional association.

Authors:  Ana Teresa Carvalho; Paulo Linhares; Lígia Castro; Maria José Sá
Journal:  Case Rep Neurol Med       Date:  2014-08-07

Review 10.  Imaging of oligodendroglioma.

Authors:  Marion Smits
Journal:  Br J Radiol       Date:  2016-02-05       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.